Tvardi Therapeutics, Inc.
TTI-109
Resolved
7days ago
Phase 1 readout · Jun 30, 2026
What's at stake
Phase 1 trial results for TTI-109 in its lead indication are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June”